Free Trial

Instil Bio Q4 2022 Earnings Report

Instil Bio logo
$18.08 -1.28 (-6.61%)
As of 03/28/2025 04:00 PM Eastern

Instil Bio EPS Results

Actual EPS
-$8.20
Consensus EPS
-$9.00
Beat/Miss
Beat by +$0.80
One Year Ago EPS
N/A

Instil Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.00 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Instil Bio Announcement Details

Quarter
Q4 2022
Time
Q4 2022 Earnings Release

Conference Call Resources

Remove Ads

Instil Bio Earnings Headlines

Instil Bio reports Q4 adjusted EPS ($1.08) vs. ($1.26) last year
Musk’s real agenda in D.C.
In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of America…
Instil Bio: Time To Hop On The Summit Wave?
JMP Securities Keeps Their Hold Rating on Instil Bio (TIL)
See More Instil Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Instil Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Instil Bio and other key companies, straight to your email.

About Instil Bio

Instil Bio (NASDAQ:TIL), a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

View Instil Bio Profile

More Earnings Resources from MarketBeat